Hyderabad, Feb 5: BioAsia 2026, Asia’s premier life sciences and healthcare forum, is set to convene an exceptional assembly of global scientific pioneers, artificial intelligence leaders, industry CEOs and policymakers at a defining inflection point for healthcare innovation. Anchored by the theme “TechBio Unleashed: AI, Automation & the Biology Revolution,” the two-day conference, scheduled for February 17–18, 2026, will explore how artificial intelligence, advanced biology and intelligent manufacturing are converging to fundamentally transform the discovery, development and delivery of therapies worldwide.
As biology becomes increasingly programmable and AI continues to compress R&D and manufacturing timelines, the TechBio paradigm is rapidly moving from experimentation to execution. BioAsia 2026 is positioned squarely at this moment—bringing together leaders who are actively shaping AI-driven discovery platforms, next-generation biologics and digitally integrated operating models across global healthcare ecosystems.
Leadership Commitment and Telangana’s Global Vision
The conference will open with inaugural addresses by Shri A. Revanth Reddy, Hon’ble Chief Minister of Telangana, and Shri D. Sridhar Babu, Hon’ble Minister for Information Technology, Electronics, Communications, Industries and Commerce. Their participation underscores the Government of Telangana’s long-term commitment to positioning Hyderabad among the world’s top five life sciences hubs.
A dedicated session on Telangana Rising Vision 2047 will outline the State’s roadmap for innovation-led growth, with a focus on advanced modalities, AI-enabled R&D, and next-generation biomanufacturing.
Global Science and AI Leaders at the Forefront of TechBio
BioAsia 2026 will feature a distinguished lineup of global leaders whose work has materially advanced modern biopharma, AI-driven science and digital healthcare.
Dr Stefan Miltenyi, Founder and President, Miltenyi Biotec (Germany), will discuss the evolution of next-generation biologics—from discovery to clinical proof and scalable CMC—drawing on his foundational contributions to cell therapy research and manufacturing platforms.
Dr Howard Y. Chang, Chief Scientific Officer, Amgen (USA), a globally recognised authority in functional genomics, epigenetics and RNA biology, will share insights into how AI-powered biology is transforming target discovery, disease understanding and precision medicine at scale.
Mr Pushmeet Kohli, Vice President of Science, Google DeepMind, will offer perspectives from the frontier of artificial intelligence, highlighting how foundational models, protein science breakthroughs and reinforcement learning are accelerating progress across biology and medicine.
Ms Madeleine Roach, Executive Vice President and Head of Business Operations, Sanofi (France), will deliver a Day Two Plenary Address on Sanofi’s AI-first transformation and the integration of digital, data and advanced analytics across global R&D, manufacturing and operations.
Mr Anton Groom, Chief AI Officer, MSD (USA), will open the flagship session on innovation-led Global Capability Centres (GCCs), sharing insights from embedding AI across one of the world’s largest pharmaceutical R&D engines.
Dr Despina Solomonidou, EVP & Global Head – Technical Research & Development, Novartis will highlight the role of digital, data-driven and automation-led CMC models in accelerating global scale-up of innovation.
Ms Rashmi Kumar, SVP & Chief Information Officer, Medtronic (USA), will speak on large-scale digital and AI transformation across MedTech to enhance product innovation and patient outcomes.
Mr Eamonn Warren, Group Vice President – Manufacturing (API & Dry Products), Eli Lilly (USA), will share perspectives on advancing automation, digital quality systems and resilient global supply chains.
Mr Badhri Srinivasan, Group CEO, Unilabs (Switzerland), will discuss the AI-enabled transformation of diagnostics, improving speed, accuracy and clinical decision-making at scale.
Global Industry Voices Shaping the Next Decade
Across nine high-impact sessions, BioAsia 2026 will host senior leaders from Amgen, Novartis, Eli Lilly, Medtronic, Sanofi, Roche, AbbVie, BMS, AstraZeneca, Novo Nordisk, Takeda, MSD, Lonza, Miltenyi Biotec, Google DeepMind and Thermo Fisher Scientific, alongside leading Indian innovators including Dr Reddy’s Laboratories, Bharat Biotech, Biocon Biologics, Zydus Lifesciences, Laurus Labs, Sai Life Sciences, Aragen, Piramal Pharma, Syngene, TCS and Apollo Hospitals.
Key discussions will examine:
What it truly takes to scale innovation across science, software and supply chains
Growth drivers and structural headwinds for pharma and biotech (2026–2030)
The evolution of next-generation biologics and advanced modalities—from discovery to manufacturing readiness
AI as a force multiplier across CRDMO and biomanufacturing value chains
A marquee CEO Conclave will bring together global industry leaders for a candid dialogue on growth, geopolitics, resilience and innovation pathways as the sector looks ahead to 2030.
GCCs, India’s Innovation Moment and Global Impact
Day Two will spotlight the rapid evolution of Global Capability Centres (GCCs) in life sciences—now emerging as strategic innovation engines rather than cost centres. Sessions will explore AI-enabled R&D, digital transformation and direct end-patient impact, alongside discussions on financing TechBio, deep-tech manufacturing and scaling breakthrough science from India to the world.
With participation from global pioneers, policymakers, investors and next-generation innovators, BioAsia 2026 will continue its legacy as a definitive platform for collaboration, insight and investment—while reinforcing Hyderabad’s position as one of the world’s most dynamic ecosystems for life sciences, biotechnology and TechBio innovation.